All In Biotech

Drug Trial Radar · NCT00660179

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Last checked: Nov 19, 2026Latest source record: Sep 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

742

Actual

Start

May 2008

Primary completion

Mar 2012

Study completion Apr 2012

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH. The main study objective is to demonstrate that macitentan (ACT-064992) prolongs time to the first morbidity or mortality event, and to evaluate the benefit/risk profile of macitentan (ACT-064992) in the treatment of patients with symptomatic PAH.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • macitentan (ACT-064992)Drug

    Tablet, 3 mg dosage, once daily

  • macitentan (ACT-064992)Drug

    Tablet, 10 mg dosage, once daily

  • placeboDrug

    Matching placebo, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event)Time frame: Up to end of treatment (data presented up to month 36)

Locations

153 sites in 38 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Pulmonary Specialists

    Pheonix, Arizona

  • GLVA Healthcare Center

    Los Angeles, California

  • University of California, San Diego

    San Diego, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Liu Center for Pulmonary Hypertension

    Torrance, California

  • University of Colorado Health Sciences Center

    Denver, Colorado

  • Mayo Clinic, Jacksonville

    Jacksonville, Florida

  • Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease

    Atlanta, Georgia

  • Pulmonary & Critical Care of Atlanta

    Atlanta, Georgia

  • Southeastern Lung Care

    Decatur, Georgia

  • University of Chicago Hospitals

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kentuckiana Pulmonary Associate, PLLC

    Louisville, Kentucky

  • Medical Center of Louisiana at New Orleans

    New Orleans, Louisiana

  • Maine Medical Center

    Portland, Maine

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • Pulmonary/Critical Care Division/Tufts New England Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • University of NJ - Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Columbia University Medical Center - Pediatric Cardiology

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Ohio Heart Health Center

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Medical Center - St. Paul University

    Dallas, Texas

  • Baylor College of Medicine and the Methodist Hospital

    Houston, Texas

  • Dept. of Pulmonary Medicine - Latter Day Saints Hospital

    Salt Lake City, Utah

  • Sentara Hospital T/A Sentara Cardiovascular Research Institute

    Norfolk, Virginia

  • Comprehensive Cardiovascular Care Group

    Milwaukee, Wisconsin

  • Fundacion Favaloro

    Buenos Aires, Argentina

  • Hospital Britanico

    Buenos Aires, Argentina

  • Sanatorio MITRE

    Buenos Aires, Argentina

  • SANATORIO OTAMENDI y MIROLI

    Buenos Aires, Argentina

  • Htal Italiano Cordoba

    Córdoba, Argentina

  • Htla privado de Cordoba

    Córdoba, Argentina

  • Instituto Cardiologia Corrientes

    Corrientes, Argentina

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.